ClinicalTrials.Veeva
Menu

Find clinical trials for COVID-19 in Durham, NC

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Infections
Coronavirus Infections
Human Influenza
Communicable Diseases
Post-Acute COVID-19 Syndrome
Syndrome
Pneumonia

COVID-19 trials near Durham, NC, USA:

SPI-1005 Treatment in Moderate COVID-19 Patients

multi-center clinical trial (RCT) of SPI-1005 in adult subjects with positive PCR test for novel SARS-CoV-2 (nCoV2) and moderate symptoms of COVID...

Invitation-only
Covid19
Corona Virus Infection
Drug: Ebselen
Drug: Placebo

Phase 2

Sound Pharmaceuticals

Durham, North Carolina, United States and 6 other locations

SPI-1005 Treatment in Severe COVID-19 Patients

multi-center clinical trial (RCT) of SPI-1005 in adult subjects with positive PCR test for novel SARS-CoV-2 (nCoV2) and severe symptoms of COVID...

Invitation-only
Covid19
Corona Virus Infection
Drug: Ebselen
Drug: Placebo

Phase 2

Sound Pharmaceuticals

Durham, North Carolina, United States and 6 other locations

A Study to Investigate the Prevention of COVID-19 withVYD222 in Adults With Immune Compromise and in Participants Aged 12 Years or Older Who Are at Risk of Exposure to SARS-CoV-2

A study to investigate the prevention of COVID-19 with VYD222 in adults with immune compromise and in participants aged 12 years or...

Active, not recruiting
COVID-19
SARS-CoV-2
Drug: VYD222 (pemivibart)
Drug: Normal saline

Phase 3

Invivyd

Morrisville, North Carolina, United States and 17 other locations

Locations recently updated

Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study

seek to enroll immunocompromised patients with Lower Tract parainfluenza infection.It also contains a sub-study to enroll patients with severe COVID...

Enrolling
COVID-19
Parainfluenza
Drug: DAS181 COVID-19
Drug: DAS181

Phase 3

Ansun Biopharma

Durham, North Carolina, United States and 66 other locations

A Study to Evaluate VXA-CoV2-3.1 COVID-19 Vaccine Against Currently Approved/Authorized mRNA COVID-19 Injectable Booster Vaccine in Adults Previously Immunized Against COVID-19 Infection

(SARS-CoV2) vaccine tablet VXA-CoV2-3.1 compared to a currently recommended vaccine for the prevention of symptomatic Coronavirus Disease 2019 (COVID...

Enrolling
COVID-19
SARS-CoV2
Biological: VXA-CoV2-3.1
Biological: COMIRNATY®

Phase 2

Vaxart

Durham, North Carolina, United States and 144 other locations

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Combined Modified RNA Vaccine Candidate Against COVID-19 and Influenza.

The purpose of this study is to understand the safety and effects of a combined influenza and COVID-19 vaccine. This combined vacci-...

Active, not recruiting
COVID-19
Influenza
Biological: COVID-19 Vaccine
Biological: Influenza and COVID-19 Combination A

Phase 3

BioNTech
BioNTech

Durham, North Carolina, United States and 162 other locations

Study Understanding Pre-Exposure pRophylaxis of NOVel Antibodies (SUPERNOVA) Sub-study: Study Understanding Pre-Exposure pRophylaxis of NOVel Antibodies (SUPERNOVA) Sub-study

known SARS-CoV-2 variants of concern for pre-exposure prophylaxis of COVID-19.The aim of the Phase I/III study (Parent Study) will -...

Active, not recruiting
COVID-19, SARS-CoV-2
Biological: AZD3152 (Sub-study)
Biological: Placebo (Parent study Sentinel Safety Cohort)

Phase 2, Phase 3

AstraZeneca
AstraZeneca

Durham, North Carolina, United States and 214 other locations

A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy Children

studies or substudies based on age group and prior history of COVID-19 vaccinations. All participants in each of the 5 sub-studies ...

Enrolling
COVID-19
SARS-CoV-2 Virus
Biological: Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 10 microgram dose
Biological: Variant-adapted BNT162b2 (Omicron XBB.1.5) 3 microgram dose

Phase 2, Phase 3

BioNTech
BioNTech

Durham, North Carolina, United States and 114 other locations

Locations recently updated

EPIC-Peds: A Study to Learn About the Study Medicine Called PF-07321332 (Nirmatrelvir)/Ritonavir in Patients Under 18 Years of Age With COVID-19 That Are Not Hospitalized But Are at Risk for Severe Disease

study treatment works in the study) of the study medicine (called nirmatrelvir/ritonavir) for potential treatment of coronavirus disease 2019 (COVID...

Enrolling
COVID-19
Drug: nirmatrelvir
Drug: ritonavir

Phase 2, Phase 3

Pfizer
Pfizer

Durham, North Carolina, United States and 109 other locations

Phase 2/3 Heterologous Boosting Study With Different Dose Levels of Monovalent SARS-CoV-2 rS Vaccines (COVID-19)

This is a Phase 2/3, randomized, double-blind study to evaluate the safety and immunogenicity of different booster dose levels of the monovalent seve...

Active, not recruiting
COVID-19
Biological: NVX-CoV2601 (5μg)
Biological: NVX-CoV2601 (35μg)

Phase 2, Phase 3

Novavax
Novavax

Raleigh, North Carolina, United States and 49 other locations

Clinical trials

Find clinical trialsTrials by location

Research sites

Find research sitesLearn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy NoticeTerms
© Copyright 2024 Veeva Systems